Background {#Sec1}
==========

Bronchopulmonary dysplasia (BPD), defined as oxygen dependence at 36 weeks of postmenstrual age (PMA), is a severe complications of extremely premature infants. The reported morbidity of BPD ranges from 24% in preterm infants born at 28 weeks to 79% in preterm infants born at 23 weeks \[[@CR1]\].The survival infants of BPD are at high risk for long-term injury to both lung and brain \[[@CR2]--[@CR4]\]. Pulmonary inflammation plays a central, modulating role in the pathogenesis of BPD \[[@CR5]--[@CR7]\]. It has been confirmed that corticosteroids have strong anti-inflammatory effects. Randomized controlled trials (RCTs) have shown that systemic administration of corticosteroids reduces the incidence of BPD but aggravate short-term and long-term adverse effects \[[@CR8]--[@CR11]\]. Theoretically, airway administration (inhalation or instillation) of corticosteroids, on the other hand, demonstrate high pulmonary deposition, low systemic bioavailability, and rapid systemic clearance, thereby reducing the adverse effects \[[@CR12], [@CR13]\].

A range of reviews address the use of inhaled corticosteroids for preventing BPD \[[@CR14], [@CR15]\]. Onland et al. \[[@CR14]\] have attempted the late use (≥7 days)) of inhaled corticosteroids to reduce BPD incidence in preterm infants and concluded that such treatment do not reduce the outcomes of BPD and death or BPD. Similarly, Shah et al. \[[@CR15]\] also concluded that early (\<2 weeks) administration of inhaled corticosteroids was ineffective for reducing the incidence of BPD in ventilated very low birth weight premature infants. However, some overlap in ages at administration of the inhaled corticosteroid existed in the included studies in their meta-analysis. In recent, a large RCT confirmed that inhalation of budesonide reduces both BPD and persistent ductus arteriosus (PDA) \[[@CR16]\]. However, there was a trend toward increased mortality. Subsequently, a meta-analysis including the RCT by Bassler D et al. \[[@CR17]\] showed that inhaled corticosteroids reduced risk for BPD and had no effect on death. Their meta-analysis included several therapeutic studies and failed to evaluate the intratracheal instillation of steroids \[[@CR18], [@CR19]\]. In addition, when valuating for the outcome of death, the meta-analysis included a study published as an abstract, which had a large impact on the results \[[@CR17], [@CR20]\]. The authors did not carry out sensitive analysis to determine the stability of the results \[[@CR17]\]. In addition, Cochrane reviews also have compared inhaled and systemic corticosteroids \[[@CR19], [@CR21], [@CR22]\]. Most of the main outcome were concluded from a small number of the studies with few infants providing data \[[@CR21], [@CR22]\].

Uncertainty prevails with regard to the use of inhalation or instillation steroids to prevent BPD in preterm infants \[[@CR23]\]. Recently, 2 RCTS about airway administration of corticosteroids (AACs) for preventing BPD and neurodevelopmental outcomes have been published \[[@CR24], [@CR25]\]. Therefore, to better understand the potential efficacy and safety of AACs for reducing the risk of BPD or/and death in preterm infants, as compared with placebo or systemic corticosteroids, we performed an up-to-date systematic review of published RCTs. We verified the robustness and reliability of our findings by implementing trial sequential analysis and sensitivity analyses.

Methods {#Sec2}
=======

Study identification {#Sec3}
--------------------

This systematic review was conducted and is reported according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR26]\]. Electronic searches were carried out in multiple databases, including PubMed, Web of Science, Embase, Cochrane Library, Clinicaltrials.gov, Controlled-trials.com, Google scholar, VIP, WangFang and proceedings of the Pediatric Academic Society meetings (from 1980) on December 31, 2016 for relevant studies. Search terms included: preterm infant, premature infant, infant-newborn, bronchopulmonary dysplasia, chronic lung diseases, anti-inflammatory agents, neurodevelopmental outcomes, steroids, glucocorticoids, corticosteroids; administration, inhalation; aerosols, budesonide, beclomethasone, dipropionate, flunisolide, and fluticasone propionate. No language restriction was applied. The protocol of this systematic review was registered before the literature search in PROSPERO (Prospero2016 CRD42016054098) \[[@CR27]\].

Eligibility criteria {#Sec4}
--------------------

Studies had to meet the following criteria: 1) randomized controlled trials; 2) infants were randomized to receive treatment with an airway administration (inhalation or instillation) of corticosteroid vs placebo or systemic corticosteroids; 3) reported more than one of the following outcome parameters: primary outcome of BPD (defined by the need for supplemental oxygen or positive pressure support at 36 weeks PMA) or/and death; secondary outcomes of the use of systemic corticosteroids, effect on extubation and not extubate (including extubated within 14 days and duration of mechanical ventilation), adverse outcomes of sepsis, hyperglycemia requiring treatment, intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC) Bell's stage \> or = II, retinopathy of prematurity (ROP), PDA requiring drug treatment or surgery, and neurodevelopmental outcomes of neurodevelopmental impairment and cerebral palsy. Exclusion criteria were: a) non-clinical studies (experimental and basic studies); b) observational or retrospective studies; c) duplicate reports or secondary or post hoc analyses of the same study population; d) lack of sufficient information on baseline or primary or secondary outcome data; and e) therapeutic study.

Assessment of the risk of bias {#Sec5}
------------------------------

Two reviewers (Zhang and Zhong) independently assessed the risk of bias of individual studies and the bias domains across studies using the Cochrane collaboration tool \[[@CR28]\]. All discrepancies were resolved by discussion and consensus. The studies were rated to be at high risk of bias, low risk of bias, or unclear risk of bias based on sequence generation, concealment of allocation, blinding of participants/parents and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting.

Data collection {#Sec6}
---------------

For each study, data were extracted independently by two reviewers (Zhang and Zhong) using a predesigned form. Any differences and disagreements in the abstracted data were discussed and resolved by consensus. Details of methodological quality, study design, analysis, and results were abstracted. For each outcome, the numeric results, the statistic used, and the *P* value were abstracted. We contacted authors of the original reports to obtain further details when information regarding any of the above information was unclear.

Statistical analysis {#Sec7}
--------------------

The statistical analyses were performed by the DerSimonian and Laird method (random-effect model) using the Review Manager meta-analysis software (version 5.3, 2012; The Cochrane Collaboration, Copenhagen, Denmark). TSA viewer version 0.9 β was used for trial sequential analysis. Treatment effect estimates for all trials were calculated, expressed as typical relative risk (RR) for dichotomous outcomes and weighted mean difference (WMD) for continuous outcomes, all with a 95% confidence interval. If the continuous measures were reported in median and inter-quartile range, mean and standard SD values were estimated using the method described by Wan et al. \[[@CR29]\]. *P* values of ≤0.05 and RR point estimate 95% CIs that excluded the null (\<1.00 or \>1.00) were considered statistically significant. Where the pooled estimates of relative risk were statistically significant. We calculated the numbers needed to treat (NNT) for all outcomes. The heterogeneity between-trial regarding treatment effects was analyzed by the χ^2^ test for heterogeneity and *I* ^2^ statistics. Heterogeneity was deemed significant when the corresponding *p*-value was \<0.1 or when the *I* ^2^ percentage was \>50 \[[@CR30]\]. Subgroup analyses were carried out to assess the source of heterogeneity. When more than 10 articles were included, the presence of publication bias was assessed and displayed through a funnel plot. Analysis by excluding studies at high risk of bias or abstract forms was part of a predefined subgroup analysis \[[@CR28]\]. Sensitivity analysis with trial sequential analysis was performed to correct for random error and repetitive testing of accumulating and sparse data; meta-analysis monitoring boundaries and required information size (meta-analysis sample size) were quantified, along with D2 (diversity adjusted information size) and adjusted 95% CIs \[[@CR31]--[@CR34]\]. Risk of type 1 error was considered 5% with a power of 80%. A clinically meaningful anticipated relative risk reduction was used based on the low bias trial \[[@CR16]\]. Trial sequential analysis 95% CI boundaries that excluded the null (\<1.00 or \>1.00) were considered statistically significant.

Results {#Sec8}
=======

Study selection {#Sec9}
---------------

Our search identified 121 potentially relevant articles during the initial electronic database search, of which 35 RCTs were involving the use of AACs in premature infants. However, only 25 (27 articles) of 35 trials presented appropriate and sufficient data for further analysis \[[@CR16], [@CR20], [@CR24], [@CR25], [@CR35]--[@CR57]\], and the remaining eight were excluded because of therapeutic study of inhaled steroids for BPD \[[@CR18], [@CR19], [@CR58]--[@CR61]\] and when the raw data in Ref. \[[@CR62], [@CR63]\] is lacking due to unable to reach the original investigators. Overall, the 20 trials of airway administration of corticosteroid (16 trials of inhaled corticosteroid and 4 trials of instillation of steroids) vs placebo included 2484 infants, and 5 trials of inhaled corticosteroid vs systemic corticosteroids included 765 infants. Two studies were published in abstract form \[[@CR20], [@CR47]\]. Two articles \[[@CR50], [@CR55]\] were follow-up studies of two included trials \[[@CR49], [@CR54]\]. Fig. [1](#Fig1){ref-type="fig"} shows the details of the selection process.Fig. 1Flowchart of the study selection process. \* Two article \[[@CR48], [@CR53]\] were follow-up study of two included trials \[[@CR47], [@CR52]\]

Characteristics of the included studies {#Sec10}
---------------------------------------

The 25 RCTs (27 articles) selected for analysis included a total of 3249 participants (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}, Table S1-S2 in Additional file [1](#MOESM1){ref-type="media"}: Table S1 and Additional file [2](#MOESM2){ref-type="media"}: Table S2) \[[@CR16], [@CR20], [@CR24], [@CR25], [@CR35]--[@CR57]\]. The publication dates of the RCTs ranged from 1993 to 2016. The AACs group vs the placebo group or systemic corticosteroids group were well matched; birth weight and gestational age did not differ significantly significance. Other aspects of respiratory treatment, including the resuscitation devices used and the criteria for using antenatal glucocorticoids as well as surfactant, were adequately described in the studies and conformed to current international guidelines \[[@CR64]--[@CR66]\]. The incidence of neonatal respiratory distress syndrome (was diagnosed based on respiratory symptoms and corresponding X-ray changes) was comparable among the airway administration of corticosteroid group and comparative groups.Table 1Characteristics of 25 RCTs reported in 27 articles and baseline characteristics of patientsStudyStudy characteristicsGroupNMale (n)GA (wk)BW (g)Antenatal glucocorticoidRDS (n)Surfactant(n)AACs vs placeboArnon \[[@CR35]\] 19961 centre\
UKT\
C15\
15NA\
NA27.5 (0.7)^a^\
27.1 (0.89)^a^1024 (92.3)^a^\
1041 (113)^a^7 (46.7%)\
8 (53.3%)NA\
NANA\
NABassler \[[@CR16]\] 201510 centres SwitzerlandT\
C437\
419NA\
NA26.1 (1.3)^a^\
26.1 (1.2)^a^798 (193)^a^\
803 (189)^a^388 (88.8%)\
383 (91.4%)NA\
NANA\
NACao \[[@CR36]\] 20161 centre\
ChinaT\
C40\
40NA\
NA30.1 (2.2)^a^\
30.7 (1.8)^a^1333 (110)^a^\
1339 (105)^a^NA\
NA40\
4040\
40Cole \[[@CR37]\] 19994 centres\
USAT\
C123\
13051\
5326 (2)^a^\
26 (2)^a^800 (193)^a^\
802 (189)^a^77 (62.6%)\
68 (52.3%)123\
12995\
97Denjean \[[@CR38]\] 19986 centres\
FranceT\
C43\
4326\
2627.6 (1.5)^a^\
27.8 (1.6)^a^1060 (218)^a^\
1082 (260)^a^11 (25.6%)\
11 (25.6%)43\
4331\
34Fok \[[@CR39]\] 19991 centre\
Hong KongT\
C27\
26NA\
NA27.9 (0.5)^a^\
27.1 (0.5)^a^993 (71)^a^\
981 (71)^a^15 (55.6%)\
13 (50.0%)NA\
NANA\
NAGiep \[[@CR40]\] 19961 centre\
USAT\
C10\
96\
326 (2.0)^a^\
25 (1.6)^a^752 (110)^a^\
784 (141)^a^4 (40.0%)\
2 (22.2%)8\
98\
9Jangaard \[[@CR41]\] 20021 centre\
GermanyT\
C30\
3013\
1327.2 (2)^a^\
27.9 (2)^a^882 (204)^a^\
917 (178)^b^15 (50.0%)\
16 (53.3%)19\
2519\
25Jonsson \[[@CR42]\] 20001 centre\
SwedenT\
C15\
158\
1125 (23,27)^b^\
26 (24,29)^b^766 (525,1122)^b^\
813 (630,1227)^b^12 (80.0%)\
10 (66.7%)14\
1514\
15Ke \[[@CR43]\]\
20161 centre\
ChinaT\
C46\
4620\
27\<32\
\<32\<1500\
\<1500NA\
NA46\
4646\
46LaForce \[[@CR44]\] 19931 centre\
USAT\
C10\
11NA\
NANA\
NA\<1500\
\<1500NA\
NANA\
NANA\
NAMerz \[[@CR45]\] 19991 centre\
GermanyT\
C12\
115\
728 (27,32)^b^\
29 (27,31)^b^1108 (820,1420)^b^\
1120 (880,1480)^b^7 (58.3%)\
7 (63.6%)12\
1110\
9Nakamura \[[@CR24]\] 20161 centre\
JapanT\
C107\
10463\
5026 (25,27)^b^\
26 (25,27)^b^783.87 (134.8)^b^\
784.06 (127.2)^b^45 (42.1%)\
42 (40.4%)90\
88NA\
NAPappagallo \[[@CR46]\] 19981 centre\
USAT\
C9\
95\
526.8 (1.1)^a^\
26.6 (0.8)^a^828 (64)^a^\
849 (89)^a^NA\
NANA\
NANA\
NATownsend \[[@CR47]\] 19981 centre\
DenverT\
C15\
178\
825.8\
25.5728\
695NA\
NA15\
17NA\
NAWen \[[@CR48]\] 20161 centre\
ChinaT\
C80\
8054\
5130.5 (2.6)^a^\
31.2 (2.3)^a^1220 (183)^a^\
1250 (167)^a^NA\
NANA\
NANA\
NAYeh \[[@CR49]\] 2008\
Kuo \[[@CR50]\] 20101 centre\
TaiwanT\
C60\
5631\
2926.4 (2.2)^a^\
26.7 (2.3)^a^881 (245)^a^\
919 (272)^a^46 (76.7%)\
42 (75.0%)60\
5660\
56Yeh \[[@CR25]\] 20161 centre\
TaiwanT\
C131\
134NA\
NA26.5 (2.2)^a^\
26.8 (2.2)^a^882 (249)^a^\
935 (283)^a^NA\
NA131\
134131\
134Yong \[[@CR20]\] 19991 centre\
UKT\
C20\
2013\
1227.4 (1.7)^a^\
27.7 (1.7)^a^1011 (223)^a^\
932 (401)^a^NA\
NANA\
NANA\
NAZimmerman \[[@CR51]\] 20001 centre\
USAT\
C20\
1912\
826 (2.0)^a^\
26 (2.0)^a^910 (198)^a^\
802 (225)^a^14 (70.0%)\
15 (78.9%)15\
1815\
18Inhaled corticosteroids vs systemic corticosteroidsDimitriou \[[@CR52]\] 19971 centre\
UKT\
C20\
20NA\
NA27 (24,30)^b^\
27 (24,31)849 (584,1270)^b^\
818 (425,1460)^b^12 (60.0%)\
11 (55.0%)NA\
NA14\
12Groneck \[[@CR53]\] 19991 centre\
GermanyT\
C7\
93\
326 (25,28)^b^\
26 (25,28)^b^800 (500,1020)^b^\
847 (660,1030)^b^NA\
NANA\
NANA\
NAHalliday \[[@CR54]\] 2001\
Wilson \[[@CR55]\] 200647 centre\
EuropeT\
C285\
285142\
16427.2 (1.9)^a^\
27.2 (1.9)^a^1002 (281)^a^\
1011 (285)^a^177 (62.1%)\
164 (57.5%)NA\
NA265\
260Rozycki \[[@CR56]\] 20031 centre\
USAT\
C46\
1523\
7\<31\
\<31\<1500\
\<15006 (13.0%)\
2 (13.3%)46\
1546\
15Suchomski \[[@CR57]\] 20021 centre\
USAT\
C51\
2725\
1926 (1.6)^a^\
26 (2.0)^a^844 (157)^a^\
843 (227)^a^34 (66.7%)\
16 (59.3%)NA\
NANA\
NA*RCTs* Randomized controlled trials, *AACs* Airway administration of corticosteroids, *RDS* Respiratory distress syndrome, *PS* Pulmonary surfactant, *AG* Antenatal glucocorticoid, *GA* Gestational age, *BW* Brith weight, ^a^means ± SD, ^b^median (25th, 75th percentiles), NA: Not Applicated Table 2Interventions used in the 25 RCTsStudyAge at enrollmentType of AACSIntervention doseMode of deliveryIntervention treatmentAACs vs placebo Arnon \[[@CR35]\]\
199615 (0.6)^a^\
14 (0.5)^a^BUD600 μg BIDMDI7 days or until the infant had been extubated Bassler \[[@CR16]\] 2015within 12 hBUD400 μg Q12H for 14 days\
200 μg Q12H for 15 daysMDIUntil extubation and no oxygen dependent or 32 weeks PMA Cao \[[@CR36]\] 2016within 6 hBUD250 μg Q8HAirway instillationUntil FIO~2~ \< 0.4 or extubation Cole \[[@CR37]\] 19995.7 (3.4)^a^\
5.4 (2.9)^a^BDP40 μg/kg for 7 days\
30 μg/kg for 7 days\
15 μg/kg for 7 days\
5-10 μg/kg for 7 daysMDI28 days Denjean \[[@CR38]\] 199810 daysBDP250 μg Q6HMDI28 days Fok \[[@CR39]\] 1999within 24 h of birthFPP250 μg\
Q12HMDI14 days Giep \[[@CR40]\] 199614 daysBDP1 mg/kg/dMDI7 days Jangaard \[[@CR41]\] 20023 yearsBDP0.2 mg/kg/dMDIUntil 28 days of age Jonsson \[[@CR42]\] 20006 daysBUD0.5 mg/times\
BIDElectronic dosimetric jet nebulizer14 days Ke \[[@CR43]\] 2016within 6 hBUD250 μg Q12HAirway instillationUntil stop respiratory support LaForce \[[@CR44]\] 199314 daysBDP50 μg Q8HA Whisper Jet nebulizer system28 days Merz \[[@CR45]\] 19993 daysBUD1.6 mg/d Q6HMDI10 days or until extubation Nakamura \[[@CR24]\] 2016within 24 h of birthFPP50 μg BIDMDIUntil 6 weeks of age or extubation Pappagallo \[[@CR46]\] 199822.6 (3.0)^a^\
19.1 (1.6)^a^DXM1 mg/kg Q8H for 7 days\
0.5 mg/kg Q8H for 7 daysA jet nebulizer10 days Townsend \[[@CR47]\] 1998at 48-96 h of ageFPP500 μg TIDMDI28 days or until extubationWen \[[@CR48]\] 2016within 24 h of birthBUD0.4 mg/kg\
Q12HMDI14 days Yeh \[[@CR49]\] 2008\
Kuo \[[@CR50]\] 20102.1 (2.2)^a^BUD0.25 mg/kg\
Q8HAirway instillationUntil the infant required ≤0.4 of FIO2 or until the infant was extubated Yeh \[[@CR25]\]\
20162.0 (1.5)^a^\
1.8 (1.6)^a^BUD0.25 mg/kg\
Q8HAirway instillationUntil the infant required ≤0.4 of FIO~2~ or until extubation Yong \[[@CR20]\]\
1999within 18 h of birthFPP250 μg\
Q12HMDI14 days Zimmerman \[[@CR51]\]\
2000within 24 h of birthBDP2MDI, Q6H for 3 days;\
2MDI, Q8H for 3 days;\
2MDI Q12H for 3 days;\
2MDI QD for 3 daysMDI12 daysInhaled corticosteroids vs systemic corticosteroids Dimitriou \[[@CR52]\]\
1997After 5 daysBUD100 μg QDA jet nebulizer10 days Groneck \[[@CR53]\]\
1999After 72 hBDP250 μg QDMDI10\~28 days Halliday \[[@CR54]\] 2001\
Wilson \[[@CR55]\] 2006\< 72 h or \> 15dBUD\<1000 g 0.4 mg BID\
\>1000 g 0.6 mg BIDMDI12 days or until extubation Rozycki \[[@CR56]\]\
2003at 14 days of ageBDPHigh: 2.4-3.7 mg/kg/d\
Mid: 1.0-1.8 mg/kg/d\
Low: 0.5-0.7 mg/kg/dMDI7 days or until extubation Suchomski \[[@CR57]\] 200212-21 days of ageBDPHigh: 800 μg/d\
Low: 400 μg/dMDIUntil extubation*RCTs* Randomized controlled trials, *BUD* Budesonide, *BDP* Beclomethasone dipropionate, *FPP* Fluticasone propionate, *MDI* metered-dose inhaler, *AACs* Airway administration of corticosteroids, *DXM* DexamethasoneNone of the trials were sponsored by the manufacturer^a^means ± SD

Although all studies attempted to include infants at risk of developing BPD, the inclusion criteria, the intervention (type of AACs), and duration of therapy varied between studies. The intervention regimens,including the prescribed dosages and administration schedules, varied considerably between the RCTs. Overall, the duration of AACs treatment ranged from 3 to 28 days, and the types of AACs included beclomethasone, budesonide, fluticasone, and dexamethasone. Delivery systems included metered dose inhaler (MDI) with a spacer device, nebulization, and airway instillation. Four studies used airway instillation of budesonide using surfactant as a vehicle \[[@CR25], [@CR36], [@CR48], [@CR49]\].

Risk of bias within individual studies {#Sec11}
--------------------------------------

Three studies were deemed to have a low risk of bias \[[@CR16], [@CR24], [@CR25]\], seven studies were deemed to have a high risk of bias \[[@CR36], [@CR38], [@CR53]--[@CR57]\] due to selection bias, detection bias, attrition bias or performance bias, and 17 studies were classified as having an unclear risk of bias \[[@CR20], [@CR35], [@CR37], [@CR39]--[@CR52]\]. Although all studies were presented as randomized trials, the method of randomization was determined to be inadequate in 17 studies \[[@CR20], [@CR35], [@CR37], [@CR39]--[@CR48], [@CR51], [@CR53], [@CR56], [@CR57]\]. Sixteen studies were found to have adequate concealment of allocation and clearly described blinding for the intervention method \[[@CR16], [@CR20], [@CR24], [@CR25], [@CR38], [@CR39], [@CR41], [@CR42], [@CR44], [@CR45], [@CR47], [@CR49]--[@CR51], [@CR56]\]. Thirteen studies were found to have adequate blinding of outcome assessment \[[@CR16], [@CR24], [@CR25], [@CR35], [@CR37], [@CR38], [@CR40], [@CR44], [@CR46], [@CR49], [@CR50], [@CR52], [@CR56]\]. Follow-up data were reported in five studies \[[@CR24], [@CR25], [@CR41], [@CR50], [@CR56]\]. Fig. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} summarise the risks of bias.Fig. 2Risk of bias graph Fig. 3Risk of bias summary for all included records

Systematic review of the findings from synthesis of the results {#Sec12}
---------------------------------------------------------------

ACCs vs placebo {#Sec13}
===============

Primary clinical outcome {#Sec14}
------------------------

### BPD {#Sec15}

Fourteen trials enrolling 2388 neonates reported on the incidence of BPD. Meta-analysis indicated that AACs was associated with a lower likelihood of BPD than was placebo (RR = 0.71, 95% CI 0.58 to 0.86, NNT = 10, *I* ^2^ = 34%, *P* = 0.0005) (Fig. [4](#Fig4){ref-type="fig"}). Trial sequential analysis correction of the 95% confidence interval (0.57 to 0.87; D^2^ = 53%) did not alter the finding of BPD morbidity benefit with AACs (Fig.[5](#Fig5){ref-type="fig"}). The finding was robust to sensitivity analysis (highest *P* value 0.007) and the subgroup of instillation of steroids had the lowest NNT (Table [3](#Tab3){ref-type="table"}), and clear evidence of publication bias was not present (Figure S1 in Additional file [3](#MOESM3){ref-type="media"}). Subgroup analysis based on type of corticosteroid showed that the incidence of BPD was significantly lower only in the group treated with budesonide compared to placebo (RR = 0.59, 95% CI 0.44 to 0.79, NNT = 8, *I* ^2^ = 40%, *P* = 0.0004) (Fig. [4](#Fig4){ref-type="fig"}). In the trial sequential analysis, the cumulative z score crossed the sequential monitoring boundary of benefit and the required information size (Fig. [5](#Fig5){ref-type="fig"}), suggesting that further studies have little chance to perturbation the finding of benefit from AACs.Fig. 4Meta-analysis of primary outcome with the use of AACs or placebo, AACs: Airway administration of corticosteroids Fig. 5Trial sequential analysis of trials reporting primary outcome comparing pooled AACs and placebo. A diversity adjusted information size was calculated using ɑ = 0.05 (two sided), β = 0.20 (power 80%), D2 = 0%, an anticipated relative risk of 29.8%, −24.5%, 13.5%, respectively, and an event proportion of 28.2%, 11.4%, 46.3%, respectively in the control arm. The cumulative z curve was constructed using a random-effect model, and a penalized z curve was also constructed. The adjusted relative risk was 0.71, 0.90, 0.81, respectively, and the 95% confidence interval was corrected to 0.57--0.87, 0.40--2.03, and 0.71--0.97, respectively, AACs: Airway administration of corticosteroids Table 3Sensitivity analysis of primary outcomes with the use of AACs or placeboOutcome or SubgroupStudiesParticipantsP valueEffect EstimateNNTBPD1423380.00050.71 \[0.58, 0.86\]10 Exclusion of high risk trials1221720.00010.70 \[0.58, 0.84\]10 Exclusion of conference abstracts132298\<0.00010.69 \[0.58, 0.83\]9 Exclusion of non English studies112006\<0.000010.72 \[0.63, 0.83\]10 Exclusion of small sample trials61861\<0.00010.69 \[0.57, 0.83\]10 Inhaled corticosteroids1017850.0030.77 \[0.65, 0.91\]14 Instillation of steroids using surfactants as carriers45530.0070.44 \[0.24, 0.79\]5Death1120410.550.75 \[0.54, 1.04\] Exclusion of high risk trials918750.400.88 \[0.56, 1.39\] Exclusion of conference abstracts1020030.991.00 \[0.75, 1.33\] Exclusion of non English studies1019610.550.90 \[0.64, 1.27\] Exclusion of small sample trials517010.981.01 \[0.70, 1.45\] Inhaled corticosteroids815800.881.03 \[0.69, 1.53\] Instillation of steroids using surfactants as carriers34610.070.67 \[0.43, 1.04\]Death or BPD817610.0030.81 \[0.71, 0.93\]12 Exclusion of conference abstracts717210.010.82 \[0.70, 0.96\]12 Exclusion of small sample trials415850.030.83 \[0.70, 0.99\]13 Inhaled corticosteroids714960.030.87 \[0.77, 0.99\]20 Instillation of steroids using surfactants as carriers1265\<0.00010.69 \[0.58, 0.82\]4*AACs* Airway administration of corticosteroids, *BPD* Bronchopulmonary dysplasia, *NNT* Numbers needed to treat

### Death {#Sec16}

Eleven trials enrolling 2041 neonates reported on the incidence of death. Meta-analysis indicated that the incidence of death was not significantly different between the AACs group and the placebo group (RR = 0.90, 95% CI 0.65 to 1.25, *I* ^2^ = 37%, *P* = 0.55) (Fig. [4](#Fig4){ref-type="fig"}). Trial sequential analysis correction of the 95% confidence interval (0.40 to 2.03; D^2^ = 55%) did demonstrate no increasing risk of death with airway administration of corticosteroid (Fig.[5](#Fig5){ref-type="fig"}). The finding was robust to sensitivity analysis (Table [3](#Tab3){ref-type="table"}), and clear evidence of publication bias was not present (Figure S1 in Additional file [3](#MOESM3){ref-type="media"}). Sensitivity analysis showed that instillation of steroids using surfactant as a vehicle had a nonsignificant reduction mortality (12.1% vs. 17.8%, RR = 0.67; 95% CI 0.43 to 1.04, *I* ^2^ = 0%, *P* = 0.07) (Table [3](#Tab3){ref-type="table"}).

### Death or BPD {#Sec17}

Eight trials enrolling 1761 neonates reported on the incidence of death or BPD. Meta-analysis indicated that airway administration of corticosteroid was associated with a lower likelihood of death or BPD than was placebo (RR = 0.81, 95% CI 0.71 to 0.93, NNT = 12, *I* ^2^ = 27%, *P* = 0.003) (Fig. [4](#Fig4){ref-type="fig"}). Trial sequential analysis correction of the 95% confidence interval (0.71 to 0.97; D^2^ = 55%) did support the finding of death or BPD morbidity benefit with airway administration of corticosteroid (Fig.[5](#Fig5){ref-type="fig"}). The finding was robust to sensitivity analysis (highest *P* value 0.03) (Table [3](#Tab3){ref-type="table"}). Subgroup analysis based on type of corticosteroid showed that the incidence of death or BPD was significantly lower only in the group treated with budesonide versus placebo (RR = 0.77, 95% CI 0.61 to 0.97, NNT = 9, *I* ^2^ = 75%, *P* = 0.03) (Fig. [4](#Fig4){ref-type="fig"}).

Secondary outcomes {#Sec18}
------------------

### Requirement for systemic steroids {#Sec19}

Fourteen trials enrolling 1886 neonates reported on the requirement for systemic steroids. A significant reduction in the administration of systemic corticosteroids was found in the group with airway administration of corticosteroids (RR = 0.86, 95% CI 0.76 to 0.97, NNT = 20 *I* ^2^ = 1%, *P* = 0.02). However, publication bias was present (Figure S1 in Additional file [3](#MOESM3){ref-type="media"}). Subgroup analysis based on type of corticosteroid showed that the requirement for systemic steroids was significantly different only with beclomethasone versus placebo (Figure S2 in Additional file [4](#MOESM4){ref-type="media"}).

### Benefit to extubation {#Sec20}

Seven trials enrolling 552 neonates reported on rates of successful extubation within 14 days. AACs have a nonsignificant increasing rates of successful extubation within 14 days (55.1% vs. 44.6%, RR = 1.53, 95% CI 1.0 to 2.33, *I* ^2^ = 66%, *P* = 0.05) (Figure S3 in Additional file [5](#MOESM5){ref-type="media"}). Seven trials enrolling 623 neonates reported on the the duration of mechanical ventilation. AACs significantly reduce the duration of mechanical ventilation compared with placebo (WMD = −2.99, 95% CI -5.10 to −0.87, *I* ^2^ = 38%, *P* = 0.006) (Figure S4 in Additional file [6](#MOESM6){ref-type="media"}).

### Adverse outcomes {#Sec21}

AACs administration had a nonsignificant reduction in incidence of PDA (40.2% vs. 45.2%, RR = 0.89, 95% CI 0.79 to 1.0, *I* ^2^ = 0%, *P* = 0.05) and NEC (7.3% vs. 9.9%, RR = 0.75, 95% CI 0.54 to 1.04, *I* ^2^ = 0%, *P* = 0.09) compared with placebo (Table S3 in Additional file [7](#MOESM7){ref-type="media"}). There were no significant differences between interventions in the likelihood of other adverse outcomes (including infection, hyperglycaemia, IVH, PVL, and ROP) (Table S3 in Additional file [7](#MOESM7){ref-type="media"}).

### Neurodevelopmental outcomes {#Sec22}

Four trials enrolling 474 neonates reported on the neurodevelopmental outcomes (neurodevelopmental impairment and cerebral palsy). Meta-analysis indicated that the incidence of neurodevelopmental impairment and cerebral palsy ware not significantly different between the airway administration of corticosteroid group and the placebo group (Table S3 in Additional file [7](#MOESM7){ref-type="media"}).

Inhaled corticosteroids vs systemic corticosteroid {#Sec23}
==================================================

Primary clinical outcome {#Sec24}
------------------------

### Bpd {#Sec25}

Four trials enrolling 747 neonates reported on the incidence of BPD. Meta-analysis indicated that the morbidity of BPD has no decisive difference between inhaled corticosteroid group and systemic corticosteroid group (RR = 1.02, 95% CI 0.85 to 1.22, *I* ^2^ = 15%, *P* = 0.81) (Fig. [6](#Fig6){ref-type="fig"}). The finding was robust to trial sequential analysis (RR = 1.02, adjusted 95% CI 0.55 to 1.88, *D* ^2^ = 0%, *P* = 0.83) (Fig. [7](#Fig7){ref-type="fig"}).Fig. 6Meta-analysis of primary outcome with the use of inhaled corticosteroids or systemic corticosteroids Fig. 7Trial sequential analysis of trials reporting primary outcome comparing pooled inhaled corticosteroids and systemic corticosteroids. A diversity adjusted information size was calculated using ɑ = 0.05 (two sided), β = 0.20 (power 80%), D2 = 0%, an anticipated relative risk of −10.5%, 18.4%, respectively, and an event proportion of 36.6%, 20.0%, respectively in the control arm. The cumulative z curve was constructed using a random-effect model, and a penalized z curve was also constructed. The adjusted relative risk was 1.08, 0.81, respectively, and the 95% confidence interval was corrected to 0.53--2.20, 0.43--1.53, respectively

### Death {#Sec26}

Five trials enrolling 762 neonates reported on the incidence of death. Meta-analysis indicated that the mortality was not significantly different between the inhaled corticosteroid group and the systemic corticosteroid group (RR = 0.81, 95% CI 0.62 to 1.06, *I* ^2^ = 0%, *P* = 0.12) (Fig. [6](#Fig6){ref-type="fig"}), and this finding was confirmed in trial sequential analysis (adjusted 95% confidence interval 0.43 to 1.53). The cumulative Z curve did not cross any boundaries for benefit or harm (Fig. [7](#Fig7){ref-type="fig"}).

Secondary outcomes {#Sec27}
------------------

### Benefit to extubation {#Sec28}

Four trials enrolling 693 neonates reported on the the duration of mechanical ventilation. Systemic corticosteroids were associated with shorter duration of mechanical ventilation (WMD = 3.21, 95% CI 0.36 to 6.06, *I* ^2^ = 10%, *P* = 0.03) (Figure S5 in Additional file [8](#MOESM8){ref-type="media"}).

### Adverse outcomes {#Sec29}

Inhaled corticosteroids were associated with less hyperglycemia (RR = 0.44, 95% CI 0.29 to 0.69, NNT = 9, *I* ^2^ = 0%, *P* = 0.0003) (Table S4 in Additional file [1](#MOESM1){ref-type="media"}). There were no significant differences between interventions in the likelihood of other adverse outcomes (including infection, NEC, PDA, PVL, and ROP) (Table S4 in Additional file [9](#MOESM9){ref-type="media"}).

### Neurodevelopmental outcomes {#Sec30}

One trial enrolling 126 neonates reported on the neurodevelopmental outcomes (impairment, disability, and cerebral palsy). There were no significant differences between interventions (Table S4 in Additional file [9](#MOESM9){ref-type="media"}).

Discussion {#Sec31}
==========

This meta-analysis including 25 trials with 3249 preterm infants at high risk of BPD estimated relative effects of AACs. The use of AACs was associated with a lower likelihood of the primary outcomes of BPD and death or BPD, and secondary outcomes of requirement for systemic steroids and the duration of mechanical ventilation than placebo, and was equivalent for preventing BPD than systemic corticosteroids. Moreover, AACs were not associated with an increased risk of death compared with placebo or systemic corticosteroids. AACs had less occurrence of hyperglycemia compared to systemic steroids.

Interpretation of the findings {#Sec32}
------------------------------

Our primary outcomes, were robust to sensitivity and trial sequential analyses. When evaluating the incidence of BPD, death, and death or BPD between AACs and placebo, consistent results was observed in trial sequential analyses and after exclusion of studies at high risk of bias, small sample, non-English literature, abstract, or studies of instillation of steroids using surfactants as carriers. In addition, sensitivity analysis showed that NNT of 5 and 4 in subgroup of instillation of steroids using surfactant as a vehicle was lower than the NNT in the inhaled corticosteroids group (NNT = 14 and 20) for preventing one case of BPD and BPD or death (Table [3](#Tab3){ref-type="table"}). Using as a vehicle surfactant may also enhance the solubility of budesonide, increase budesonide absorption, and strengthen the function of anti-inflammatory effects \[[@CR25], [@CR67]\]. Trial sequential analysis corrected the 95% CIs of the already statistically significant point estimates for main comparison of an airway administration of corticosteroid with the placebo through accounting for random error and repetitive testing of accumulating sparse data. In our analysis of incidence of BPD and death or BPD between AACs and placebo, the cumulative z score entered the futility area, indicating further trials are not required. Considering the overall morbidity, no association with benefit or harm can be found between groups, but the trial sequential analysis suggested it would be unnecessary to carry out more trials on this outcome. In our analysis of neurodevelopmental outcome between AACs and placebo, AACs did not increase neurodevelopmental impairment. Futhermore, inhaled corticosteroid also did not increase mortality and is similar in preventing BPD compared with systemic corticosteroids. The information size for the comparison of inhaled corticosteroids with systemic corticosteroids was too low to require futility boundaries in trial sequential analysis. European Consensus Guidelines on the Management of Respiratory Distress Syndrome do not recommend the use of inhaled corticosteroid for preventing BPD until further safety data become available \[[@CR68]\]. The benefit of preventing BPD and death or BPD associated with AACs found in this systematic review could inform future updates of these and other clinical guidelines.

Comparison with other studies {#Sec33}
-----------------------------

Several systematic reviews have evaluated inhaled corticosteroids in the prevention of BPD \[[@CR14], [@CR15], [@CR17], [@CR21], [@CR22]\]. A recent meta-analysis aimed to assess inhaled corticosteroids for BPD in preterm infants \[[@CR17]\]. The evidence from this meta-analysis supported inhaled corticosteroids, especially budesonide, as a potentially efficacious and safe therapy for the prevention or treatment of BPD in preterm infants \[[@CR17]\]. However they fail to implement sensitivity and subgroup analysis for the result of heterogeneity. In addition, they did not evaluate the advantage on inhaled corticosteroids compared with sysetmic corticosteroids. The previous Cochrane reviews examined either inhalation or systemic corticosteroids, further divided into early and late phases according to the time of administration. Hence, the analysis used 1 week after birth as a boundary \[[@CR21], [@CR22]\] However, in our meta-analysis, the duration of inhalation of corticosteroids ranged from 3 to 29 days, which was different from studies on intravenous administration, for which the course was about 1 week. For a long course of AACs, the boundary of 1 week after birth is sufficient to reflect the differences of AACs. Studies set the first delivery time from 12 h to 14 days after birth and the time span was long (Table [1](#Tab1){ref-type="table"}). Therefore, we hypothesize that the subgroup analysis with 1 week after birth as the boundary is not reliable, and it is difficult to follow. The dose and duration of the AACs in each study were not the same, making it difficult to determine the exact dose and the course of corticosteroids that is supposed to be beneficial even via subgroup analysis. We believe that a unified drug delivery time and course of treatment are very important for developing precise treatment and firm recommendations.

Strengths and limitations of this review {#Sec34}
----------------------------------------

The results of our analysis confirm those of the previous systematic reviews while improving their precision and further reducing the role of contingency. A major strength of present systematic review is the use of the robust Cochrane methodology \[[@CR26], [@CR28], [@CR30]\], and the meta-analysis is further challenged with trial sequential analysis to correct for random error and repetitive testing, which often is biased towards an intervention \[[@CR31]--[@CR33]\]. Our meta-analysis did focuse on bias and quality of evidence of included studies in accordance with GRADE \[[@CR69]\]. Predefined sensitivity, subgroup analysis, and trial sequential analyses that included assessment of bias and clinically heterogenous groups were presented to aid healthcare professionals for clinical decisions. However, subtle underlying bias of the trials included in the review remains a possible limitation, as in any other systematic review although we excluded the studies that are at high risk of bias.

Admittedly, several limitations in our meta-analysis might have affected the interpretation of findings. First, the trials analyzed differed in their study design and clinical characteristics of the study participants. The effect on mortality and BPD might be quite different between very preterm infants (GA: 28\~32 weeks) and extremely preterm infants (GA \< 28 weeks), and subgroup analysis based on GA or BW could not be done due to the lack of individual patient data. For extremely preterm infants, the BPD definition is based on respiratory support and oxygen requirements at 36 weeks, which may be dependent on local practices and saturation targets. Despite attempts to standardize the definition of BPD, wide variation among centers has been reported with the diagnosis of BPD ranging from 6 to 57% depending on the definition chosen \[[@CR70]\]. Hence the target population in each studies may be very different. The duration, dose, type, and inhalation or instillation of steroids using surfactants as carriers also were inconsistent across studies. Although we validated the stability of the result of our meta-analysis by subgroup analysis and sensitivity, the direct comparison between inhalation and instillation steroids using surfactant as a vehicle was lacking. Furthermore, there were few studies on AACs compared with systemic corticosteroids, and not all trials presented the primary and secondary outcomes, be especially neurodevelopmental outcomes. To some extent, the clinical diversity still potentially compromises the validity of the current results, even though we have pooled the data as if they were from clinically homogeneous studies. Third, formal tests for publication bias are still lacking. In principle, this should not interfere with the meta-analysis results, because publication bias generally results in an overestimation of the effect estimates.

Conclusions {#Sec35}
===========

In this meta-analysis with sequential analysis, compared with placebo, AACs (especially instillation of budesonide using surfactant as a vehicle) was found to reduce the risk of BPD and death or BPD, with no assocaited increase in mortality and neurodevelopmental impairment. Compared with systemic corticosteroids, inhaled corticosteroids were similar for preventing BPD. The appropriate dose and duration, inhalation or instillation with surfactant as a vehicle and the long-term safety of AACs needs to be assessed in large trials.
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AACs

:   Airway administration of corticosteroids

BPD

:   Bronchopulmonary dysplasia

IVH

:   Intraventricular hemorrhage

MDI

:   Metered dose inhaler

NEC

:   Necrotizing enterocolitis

NNT

:   Number needed to treat

PDA

:   Patent ductus arteriosus

PMA

:   Postmenstrual age

PVL

:   Periventricular leukomalacia

RCTs

:   Randomized controlled trials

ROP

:   Retinopathy of prematurity

RR

:   Relative risk

WMD

:   Weighted mean difference
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